This educational activity is supported by educational grants from the following companies: Celgene Corporation and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Adjunctive and Supportive Care in Multiple Myeloma

Sandra E. Kurtin, RN, MS, AOCN®, ANP-C
The University of Arizona Cancer Center

Patients with multiple myeloma are at risk for developing additional comorbidities, complications from the disease, and/or treatment-related comorbidities, such as thromboembolism, pathologic fractures, renal disease, neutropenia, or neuropathy. Advanced practitioners have a major role in overseeing supportive care and symptom management. Therefore, it is imperative that advanced practitioners have knowledge and expertise in this area. This activity addresses these issues, providing advanced practitioners with needed strategies necessary to provide the best patient outcomes.

Related Activities

Management of Newly Diagnosed Multiple Myeloma Patients

Relapsed or Refractory Multiple Myeloma

Management of Multiple Myeloma Patients Treated With Immunotherapy

Risk Stratification in Multiple Myeloma

How do IMIDs work?

What does an advanced practitioner need to know to create an optimal treatment regimen for the individual patient and explain the benefits and risks of the available choice to patients?

Briefly define low-risk vs high risk patient and how risk stratification influences treatment decisions.

What are the toxicities associated with the agents used for multiple myeloma?

What are some monitoring parameters for toxicities to establish?

How can I increase patient adherence to treatment regimens for multiple myeloma?

Bone Marrow Biopsy Demonstration Video

Copyright © 2016 Harborside Press, LLC All rights reserved.                Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact
Copyright Notice/Disclaimer
Bot trap - Don't go here
click me